Adage Capital Partners Gp, L.L.C. Arcus Biosciences, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 443,000 shares of RCUS stock, worth $3.98 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
443,000Holding current value
$3.98 Million% of portfolio
0.01%Shares
4 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.2MCall Options Held
288KPut Options Held
138K-
Black Rock Inc. New York, NY9.76MShares$87.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.39MShares$48.4 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.52MShares$31.7 Million0.39% of portfolio
-
State Street Corp Boston, MA2.99MShares$26.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2MShares$17.9 Million0.07% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $649M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...